The Seroepidemiology of Hepatitis A and B in a Japanese Town

Akbar, Sk. Md. Fazle; Onji, Morikazu; Kanaoka, M; Horiike, Norio; Michitaka, Kojiro; Masumoto, T.; Nonaka, Takashi; Kanda, Kimitoshi; Kajino, Kazunori; Kumamoto, Izumi; Nadano, Seijin; Ohta, Yasuyuki

doi:10.1177/101053959300600204

Cited by 10 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Whereas Korea and the USA have recommended routine vaccination against HBV for all infants since 1991, Japan started routine vaccination against HBV for all infants in 2014 (34). As a consequence, the seroprevalences of anti-HBs antibody in Korea and the USA were 63%–72.9% and 19.5%–60.5%, respectively, depending on the age group (2935363738). In contrast, the prevalence rate of anti-HBs antibody was only 5.1% in Japan (2935363738).…”

Section: Discussionmentioning

confidence: 99%

Antibodies against Hepatitis A and Hepatitis B Virus in Intravenous Immunoglobulin Products

Lee

Kim

2016

J Korean Med Sci

View full text Add to dashboard Cite

The worldwide seroprevalence of hepatitis A virus (HAV) and hepatitis B virus (HBV) has changed over the last two decades, indicating a declining incidence of HAV and HBV infections. Therefore, vaccinations against HAV and HBV are recommended for unimmunized people before traveling to an endemic area. Unfortunately, primary antibody deficiency (PAD) patients can only obtain humoral immunity through intravenous immunoglobulin G (IVIG) replacement and not from vaccination because of a defect in antibody production. However, few studies have analyzed the titers of antibodies against HAV or HBV in IVIG products. In this study, the titers of anti-HAV and anti-HBs antibodies were measured in nineteen lots of IVIG products from five manufacturers from three countries (A, B from Korea; C, D from Japan; and E from the USA), and trough titers in plasma were estimated. Concentrations of anti-HAV antibody ranged from 1,888–8,927 mIU/mL and estimated trough titers exceeded the minimal protective value in all evaluated IVIG products. Concentrations of anti-HBs antibody ranged from 438–965 mIU/mL in products A and B and were 157, 123, and 1,945 mIU/mL in products C, D, and E, respectively. Estimated trough titers in products A, B, and E exceeded the minimal protective value but those in products C and D did not reach this threshold. These data demonstrated that available IVIG products generally provide sufficient antibodies against HAV and HBV to protect patients with PAD, although the trough concentrations of anti-HBs antibody in two IVIG products did not reach the minimum protective value.

show abstract

Section: Discussionmentioning

confidence: 99%

Antibodies against Hepatitis A and Hepatitis B Virus in Intravenous Immunoglobulin Products

Lee

Kim

2016

J Korean Med Sci

View full text Add to dashboard Cite

show abstract

“…However, a universal vaccination program for all children has not been established yet. As a result, most Japanese young adults are therefore considered to remain susceptible to HBV 5,8 …”

Section: Introductionmentioning

confidence: 99%

“…As a result, most Japanese young adults are therefore considered to remain susceptible to HBV. 5,8 Under these circumstances, the occurrence of adult acute HBV infection is currently showing an increasing tendency in Japan. It tends to occur mostly in young men, and genotype A, which was imported from overseas and is mainly transmitted by sexual contact with multiple partners, shows an increasing proportion.…”

Section: Introductionmentioning

confidence: 99%